Literature DB >> 22010928

ABVD versus BEACOPP for Hodgkin's lymphoma.

Peter Borchmann, Volker Diehl, Andreas Engert.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22010928     DOI： 10.1056/NEJMc1109618

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  State of the art in the treatment of Hodgkin lymphoma.

Authors:  Peter Borchmann; Dennis A Eichenauer; Andreas Engert
Journal:  Nat Rev Clin Oncol       Date:  2012-06-12       Impact factor: 66.675

Review 2.  The GHSG Approach to Treating Hodgkin's Lymphoma.

Authors:  Paul J Bröckelmann; Andreas Engert
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

3.  Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low-dose CT.

Authors:  Anat Ilivitzki; Lea Radan; Miriam Ben-Arush; Ora Israel; Ayelet Ben-Barak
Journal:  Pediatr Radiol       Date:  2012-11-14

Review 4.  Advanced hodgkin lymphoma: a new era of therapy.

Authors:  Eldad J Dann
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-09-05       Impact factor: 2.576

5.  CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function.

Authors:  Keyur Thakar; Aileen Novero; Arundhati Das; Adriana Lisinschi; Bella Mehta; Tauseef Ahmed; Delong Liu
Journal:  Biomark Res       Date:  2014-06-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.